| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism |
|
Medicine details |
|
| Medicine name | rivaroxaban (Xarelto®) |
| Formulation | 15 mg, 20 mg film-coated tablet |
| Reference number | 1522 |
| Indication | Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults |
| Company | Bayer Healthcare Pharmaceuticals |
| BNF chapter | Cardiovascular system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 29/11/2012 |
| NICE guidance | TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism |